CN1180797C - Medicine for preventing and curing osteoporosis - Google Patents
Medicine for preventing and curing osteoporosis Download PDFInfo
- Publication number
- CN1180797C CN1180797C CNB011002859A CN01100285A CN1180797C CN 1180797 C CN1180797 C CN 1180797C CN B011002859 A CNB011002859 A CN B011002859A CN 01100285 A CN01100285 A CN 01100285A CN 1180797 C CN1180797 C CN 1180797C
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- osteoporosis
- calcium
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a medicine composition for curing and preventing osteoporosis. The medicine composition is characterized in that kudzuvine root, total flavonoids extracted from soybean, and calcium compounds are used as raw materials and combined according to a certain proportion and the traditional medical preparation technology, and auxiliary materials are added. The medicine composition of the present invention can be prepared into oral medicines which have various dosage forms, such as tablets, capsules, drop pills, liquid, etc. and have the efficiency of curing and preventing osteoporosis. The present invention has the characteristics of simple preparation technology, conspicuous curative effect, and no toxic or side effect and provides an ideal medicine for preventing and curing osteoporosis for clinics.
Description
Technical field
The present invention relates to a kind of medicine of protect against osteoporosis.Exactly relating to a kind of is raw material with Radix Puerariae total flavones, Semen sojae atricolor total flavones and calcium compounds, three blended by a certain percentage pharmaceutical composition.
Background technology
Owing to decrease in estrogen, bone resorption and bone formation take off the coupling connection after women's menopause, and bone formation reduces, and bone resorption strengthens, and bone calcium is lost, and causes osteoporosis.Therefore, postmenopausal osteoporosis is the high female old aged people degenerative disease of a kind of sickness rate.Clinical used medicine has multiple at present: as estrogen, calcium preparation, diphosphate, parathyroid hormone etc., but all there is toxic and side effects in various degree in these medicines.Just be used for the treatment of postmenopausal osteoporosis as estrogen since the eighties by clinical first-selection.Postmenopausal women's controversies in hormone replacement in the elderly can reduce osteoporotic fracture incidence rate and cardiovascular disease incidence rate, improves total survival rate.But breast deliquescing, vaginal hemorrhage, emotion agitation and thromboembolism can appear in life-time service estrogen, and the danger of increasing breast carcinoma and onset of endometrial cancer rate is also arranged in addition.Though various Chinese medicine that is used for the treatment of osteoporosis less or have no side effect, have the prescription prescription and change complicated, the course of treatment is long, curative effect is slow and uncertain therapeutic efficacy such as cuts at deficiency.
Main component isoflavone in the total flavones that extracts in Radix Puerariae and the Semen sojae atricolor is a phytoestrogen, can play estrogen-like effects for the low estrogen level, can prevent and treat decrease in estrogen produces behind the postmenopausal women disease such as osteoporosis, blood fat rising etc.Horizontal person then can produce estrogenic antagonist to high estrogen.
Summary of the invention
The objective of the invention is to finish by following method:
Extract total flavones with the methanol cold-maceration in Radix Puerariae, extract total flavones with aquiferous ethanol under certain pH in Semen sojae atricolor, the prescription of its pharmacy can be:
Radix Puerariae total flavones: 7.2%～12.1%
Semen sojae atricolor total flavones: 4.5%～6.6%
Calcium containing compound: 24.3%～40.3%
Traditional drugs goods adjuvant: 41%～64%
Traditional drugs goods adjuvant is the required forming agent of different dosage forms such as tablet, capsule, drop pill, oral liquid, distilled water etc.Calcium containing compound is calcium gluconate or calcium lactate or dalcium biphosphate or calcium carbonate.
Zoopery shows, gives the oral medicine of the present invention of removal ovary rat after two months, and the rat femur resistance to bending strengthens, and bone trabecula density increases, and compares with ovariectomized group that there were significant differences.Add medicine of the present invention in culture medium, In vitro culture mice embryonic long bone osteoclast number is reduced, the hypertrophic chondrocyte number increases, the bone alkaline phosphatase increased activity, and bone hydroxyproline, calcium, phosphorus content increase, and compare with matched group that there were significant differences.Show that medicine of the present invention can suppress bone resorption, promote bone formation, and have the effect of control postmenopausal osteoporosis.Through 1 year animal experimental observation, use medicine of the present invention animal is not found any toxic and side effects.
The specific embodiment
Use the zoopery result of medicine of the present invention
Experimental example one
Select 20 of Wistar female rats for use, behind the row bilateral oophorectomy, be divided into 10 of matched groups immediately, 10 of experimental grouies.
The experimental group medicine gastric infusion of the present invention that does not contain adjuvant, dosage is 0.3g/kg, 1 time/day, logotype is put to death all animals after February, the femur that cuts every rat is respectively done the resistance to bending experiment, fixing, embedding, section, dyeing, measurement result shows that matched group and experimental group have significant difference (p＜0.05).
The influence of table 1 pair removal ovary rat (x ± s, n=10)
Project matched group experimental group
Trabecula Bone Volume density 182.55 ± 80.21 218.15 ± 65.79
Average 18.84 ± 0.91 22.01 ± 0.78 is loaded with in femur bending failure
Experimental example two
Get 16d gestational age female mice, separate complete forelimb ulna under anatomic microscope, place the BGJb culture medium that contains 10%FBS, add rotating and culturing 48h behind the medicine of the present invention, drug level is 15 μ g/ml (in total flavones).Light microscopic is key osteoclast of counting and epiphyseal plate hypertrophic zone chondrocyte number down.And measure its alkaline phosphatase activities and hydroxyproline, calcium, phosphorus content.Experimental result demonstration experimental group has been compared significant difference (p＜0.05 or p＜0.01) with matched group.
The influence of table 2 pair In vitro culture tire Mus long bone growth (x ± s, n=18)
Project matched group experimental group
Osteoclast number 12.8 ± 2.4 5.8 ± 1.7
Hypertrophic chondrocyte number 10.6 ± 1.8 16.1 ± 2.1
Alkaline phosphatase activities 0.11 ± 0.01 0.19 ± 0.03
Hydroxyproline 2.15 ± 0.12 3.01 ± 0.34
Calcium 3.85 ± 0.14 5.48 ± 0.10
Phosphorus 2.18 ± 0.19 3.68 ± 0.23
Example of the present invention one is for to make tablet with product
Radix Puerariae total flavones 12.1%
Semen sojae atricolor total flavones 6.6%
Calcium gluconate 40.3%
Starch 40.0%
15% starch slurry is an amount of
Magnesium stearate is an amount of
Above-mentioned prescription is made tablet by traditional processing mode.
Example of the present invention two is for to make capsule with product
Radix Puerariae total flavones 7.2%
Semen sojae atricolor total flavones 4.5%
Calcium lactate 24.3%
Starch 64.0%
Example of the present invention three is for to make capsule with product
Radix Puerariae total flavones 7.2%
Semen sojae atricolor total flavones 4.5%
Dalcium biphosphate 28.3%
Starch 60.0%
By traditional pharmaceutical technology preparation, the capsule of packing into No. 2.
Calcium gluconate, calcium lactate, dalcium biphosphate, calcium carbonate
Claims (2)
1. the medicine of a protect against osteoporosis is characterized in that it by Radix Puerariae total flavones 7.2%～12.1%, Semen sojae atricolor total flavones 4.5%～6.6%, and calcium containing compound 24.3%～40.3%, traditional drugs goods adjuvant 41%～64% is formed.
2. the medicine of a kind of protect against osteoporosis according to claim 1 is characterized in that calcium containing compound is: calcium gluconate or calcium lactate or dalcium biphosphate or calcium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011002859A CN1180797C (en) | 2001-01-16 | 2001-01-16 | Medicine for preventing and curing osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011002859A CN1180797C (en) | 2001-01-16 | 2001-01-16 | Medicine for preventing and curing osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1364511A CN1364511A (en) | 2002-08-21 |
| CN1180797C true CN1180797C (en) | 2004-12-22 |
Family
ID=4651458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011002859A Expired - Fee Related CN1180797C (en) | 2001-01-16 | 2001-01-16 | Medicine for preventing and curing osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180797C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1293870C (en) * | 2003-12-26 | 2007-01-10 | 吴英萍 | Medicine for treating osteoporosis and its preparing method |
| CN1615743B (en) * | 2004-11-02 | 2010-04-28 | 尹渭元 | Compound soybean isoflavone health tablet |
| CN104147100A (en) * | 2014-08-19 | 2014-11-19 | 安徽九方制药有限公司 | Pueraria flavonid medical application |
-
2001
- 2001-01-16 CN CNB011002859A patent/CN1180797C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1364511A (en) | 2002-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| Kulczyński et al. | Puerarin—an isoflavone with beneficial effects on bone health | |
| US6399645B1 (en) | Chemoprevention and treatment of cervical or vaginal neoplasia | |
| CN102397550B (en) | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis | |
| CN1142767A (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
| CN1180797C (en) | Medicine for preventing and curing osteoporosis | |
| CN113116897B (en) | Application of magnoflorine in preparation of bone-regulating drug synergist and drug composition containing magnoflorine | |
| CN1718223A (en) | Medicine for treating osteoporosis contg. astraglus base and stanozolol | |
| CN102266415A (en) | Application of compound traditional Chinese medicine to prevention and treatment of osteoporosis disease | |
| CN102631363A (en) | Application of tectoridin in preparing medicine for preventing osteoporosis | |
| QIN et al. | Prevention and treatment of osteoporosis with traditional herbal medicine | |
| CN1781510A (en) | Use of sea-buckthorn fruit oil and/or fruit slag oil in preparing medicine for treating osteoporosis | |
| CN1148213C (en) | Composite medicine for treating osteoporosis | |
| WO2019134534A1 (en) | Use of e-10-hydroxyl-2-decylenic acid in preparation of medicine or health care product for preventing and treating osteoporosis | |
| CN101401804A (en) | Uses of salvianolic acid B in preparing medicament formulation for preventing and controlling osteoporosis | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN109771424B (en) | Pharmaceutical composition for preventing and treating senile type II diabetic osteoporosis and application thereof | |
| CN103720710A (en) | Pharmaceutical composition capable of increasing bone density and preparation method of pharmaceutical composition | |
| CN101579389B (en) | Medicinal composition for treating osteoporosis | |
| CN101125147B (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| CN1209115C (en) | Active extracted composition of teasel root and notoginseng and use in medicine | |
| CN110876766A (en) | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones | |
| CN103356606B (en) | The purposes of aesculetin | |
| WO2024154990A1 (en) | Pharmaceutical composition comprising neorhodomela munita extract for preventing or treating bone disease | |
| CN1176685C (en) | Medicine for preventing and treating coronary heart disease and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041222 Termination date: 20100220 |